12,372 trials
Allergic Asthma Due to Dermatophagoides Farinae · Allergic Asthma Due to Dermatophagoides Pteronyssinus · Allergic Rhinitis Due to House Dust Mite
Primary: Annualized Rate of Clinically Relevant Asthma Exacerbations — 0.18; 0.21 Exacerbations per year per participant — p=0.5412
Healthy Volunteers (Meningococcal Infection)
Primary: Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Following Last Vaccination With MenACYW…
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Primary: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) — -21.345; -8.150 meters — p=0.0162
Non-obstructive Azoospermia
Primary: Pain Score as Measured by the NRS-11 Scale — 1.91; 3.05; 2.27; 3.24 scores on a scale — p=0.01
Molybdenum Cofactor Deficiency, Type A
Primary: Overall Survival — 3 Participants
Malignant Neoplasm · Nausea · Vomiting
Primary: Change in Nausea Numerical Rating Scale (NRS) Between Day 5 and Day 15 — -2.0; -2.3 score on a scale — p=0.98
Influenza
Primary: Number of Subjects Developing Influenza Infection, as Confirmed by Viral Culture and Typing of Naso-pharyngeal Specimens — 35; 62 Participants
Atopic Dermatitis
Primary: Number of Treatment Emergent Adverse Events (TEAEs) — 14717 Number of Events
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019 — 7.6; 7.6; 5.5 Months — p=0.0001
Small Cell Lung Cancer
Primary: Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs) — 5; 25; 4; 9 Participants
Parkinsonian Syndrome · Parkinson Disease(PD) · Multiple System Atrophy (MSA)
Primary: Sensitivity Analysis of the Blinded Independent Read of DaTSCAN™ SPECT Images — 0.851; 0.865; 0.919 ratio
Dry Eye Disease (DED)
Primary: Number of Subjects Reporting Any Adverse Events — 97 Participants
Ulcerative Colitis
Primary: Percentage of Participants Achieving Clinical Remission at Week 40 of Study APD334-308 — 7.1; 25.0 Percentage of participants
Osteoarthritis of the Knee or Hip
Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) — 1055; 840; 885; 185 Participants
Stomach Neoplasms
Primary: Overall Survival (OS) in All Participants — 12.9; 11.5 Months — p=<0.0001